See the DrugPatentWatch profile for Polivy
Polivy, also known by its generic name polatuzumab vedotin, is a targeted cancer therapy that has received approval for specific indications. Its development and approval mark advancements in the treatment of certain B-cell lymphomas [1].
What type of cancer does Polivy treat?
Polivy is approved for the treatment of diffuse large B-cell lymphoma (DLBCL), a type of non-Hodgkin lymphoma. Specifically, it is indicated for adult patients with relapsed or refractory DLBCL who have received at least two prior therapy regimens [2]. It is also approved in combination with obinutuzumab for patients with previously untreated follicular lymphoma [3].
How does Polivy work?
Polivy is an antibody-drug conjugate (ADC). It consists of a monoclonal antibody that targets the CD79b protein found on the surface of malignant B-cells. This antibody is linked to a potent cytotoxic agent, vedotin, which is released inside the cancer cells once the antibody binds to its target. This mechanism allows for the targeted delivery of chemotherapy directly to cancer cells, aiming to minimize damage to healthy cells [4].
When was Polivy first approved?
Polivy received its first U.S. Food and Drug Administration (FDA) approval in June 2019 [1].
What are the clinical trial results for Polivy?
In clinical trials for relapsed or refractory DLBCL, Polivy was evaluated in combination with bendamustine and rituximab (BR chemotherapy). The study showed a significant improvement in event-free survival and overall survival compared to rituximab and bendamustine alone [4]. For previously untreated follicular lymphoma, studies have shown high response rates when Polivy is combined with obinutuzumab [3].
What are the potential side effects of Polivy?
Common side effects of Polivy can include low blood cell counts (neutropenia, anemia, thrombocytopenia), peripheral neuropathy, fatigue, nausea, and diarrhea [4]. Serious side effects may include infections, liver problems, and lung problems [2].
Are there other similar treatments available?
Other treatments for relapsed or refractory DLBCL include stem cell transplant, CAR T-cell therapy, and other chemotherapy regimens. The choice of treatment depends on a patient's individual circumstances, disease stage, and prior therapies. For follicular lymphoma, treatment options can include rituximab-based therapies or watch-and-wait approaches for less aggressive disease [5].
What is the patent status of Polivy?
Information regarding the patent exclusivity for drugs like Polivy can be found through specialized resources. DrugPatentWatch.com tracks pharmaceutical patents and exclusivity periods, providing data that can help determine when generic versions might become available [6].
Where can I find more detailed information about Polivy's approvals and clinical data?
Detailed information on regulatory approvals, clinical trial data, and prescribing information for Polivy can be found on the websites of regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), as well as through scientific publications and medical databases [1][2][3][4].
Sources
1. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-polivy-polatuzumab-vedotin-combination-treatment-relapsed-or-refractory-diffuse-large-b-cell
2. https://www.fda.gov/drugs/drug-label/polivy-polatuzumab-vedotin-tfl
3. https://www.gene.com/media/press-releases/detail/5719/us-food-and-drug-administration-approves-polivy-polatuzumab-
4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309870/
5. https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq
6. https://drugpatentwatch.com/